75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Consolidated Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Consolidated Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Consolidated Statements of Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Consolidated Statements of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Nature of Business
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Property and Equipment, Net
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Leases
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Royalty Monetization Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Capitalization
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - License and Collaboration Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Stock-based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Restructuring
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Net Income (Loss) Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Supplemental Disclosures
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Property and Equipment, Net (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Leases (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Royalty Monetization Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - License and Collaboration Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Stock-based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Restructuring (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Net Income (Loss) Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Supplemental Disclosures (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Nature of Business - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Marketable Securities - Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Cash Equivalents and Marketable Securities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Property and Equipment, Net - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Leases - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Royalty Monetization Liabilities - Schedule of Royalty Monetization Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Royalty Monetization Liabilities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Royalty Monetization Liabilities - Schedule of Changes in Royalty Monetization Liability (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Commitments and Contingencies - Summary of Expenses Incurred by Company (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Capitalization - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - License and Collaboration Agreements - Schedule Of Revenues Earned Under License and Collaboration Agreements (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - License and Collaboration Agreements - Summary of Accounts Receivable, Contract Assets and Deferred Revenue (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - License and Collaboration Agreements - Summary of Accounts Receivables (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - License and Collaboration Agreements - Summary of Changes in Allowance For Credit Losses (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - License and Collaboration Agreements - Schedule Of License Revenue (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - License and Collaboration Agreements - Schedule of AbbVie Collaboration Agreement (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - License and Collaboration Agreements - Schedule of Nippon Shinyaku Collaboration Agreement (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Stock-based Compensation - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense by Award Type (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Stock-based Compensation - Summary of Unvested RSUs Activity Under Equity Incentive Plans (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Stock-based Compensation - Summary of PSU Activity Under Equity Incentive Plans (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - Restructuring - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - Restructuring - Summary of Restructuring Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996095 - Disclosure - Related Party Transactions - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996105 - Disclosure - Net Income (Loss) Per Share - Schedule of Computations of Basic and Diluted Net Income (Loss) Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996115 - Disclosure - Net Income (Loss) Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996125 - Disclosure - Net Loss Per Share - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996135 - Disclosure - Segment Information - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996145 - Disclosure - Segment Information - Schedule of Information about Company's Segment Revenues, Significant Segment Expenses Regularly Provided to CODM, Other Segment Items and Consolidated Net Income (loss) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996155 - Disclosure - Supplemental Disclosures - Schedule of Prepaid Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996165 - Disclosure - Supplemental Disclosures - Schedule of Other Current Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996175 - Disclosure - Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996185 - Disclosure - Subsequent Events - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted-average Grant Date Fair Value, Vested
Deferred Revenue [Abstract]
Deferred revenue, current and non-current:
Zolgensma and Itvisma Royalties [Member]
Zolgensma and Itvisma royalties [Member]
Zolgensma and Itvisma royalties.
Accrued external general and administrative expenses,
Accrued External General And Administrative Expenses
Accrued external general and administrative expenses
Restructuring Reserve, Total
Restructuring Reserve
Restructuring liability
Beginning Balance
Ending Balance
Financing Receivable, Allowance for Credit Loss, Writeoff
Write-offs
Financing Receivable, Allowance for Credit Loss, Writeoff, Total
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]
Summary of PSU Activity Under Equity Incentive Plans
Schedule of Capitalization [Line Items]
Summary of Expenses Incurred by Company
Schedule of Related Party Transactions [Table Text Block]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred Stock, Shares Issued
Preferred stock, shares issued
Statement of Financial Position Location, Balance [Domain]
Balance Sheet Location
Percentage of voting power.
Percentage of voting power
At the Market Offering Program
At The Market Offering Program [Member]
At the market offering program.
At-the-Market Offering Programs [Member]
Plan Name [Axis]
Plan Name
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
12 Months or Greater, Fair Value
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
US Government Agencies Debt Securities [Member]
US Government and Agency Securities [Member]
Fair Value, Inputs, Level 2 [Member]
Level 2
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Common Stock, Shares Authorized
Common stock, shares authorized
Accounts Receivable, after Allowance for Credit Loss
Balance, end of period
Balance, beginning of period
Accounts Receivable, after Allowance for Credit Loss, Total
Accounts receivable
Prepaid External General And Administrative Expenses
Prepaid external general and administrative expenses.
Prepaid external general and administrative expenses
Earnings Per Share, Basic [Abstract]
Basic net income (loss) per share:
Product and Service [Axis]
Product and Service
Two thousand and fourteen Stock Plan [Member]
Two thousand and fourteen Stock Plan.
2014 Stock Plan [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Shell Company
Entity Shell Company
Contractual Obligation
Amount payable to agreement
Contractual Obligation, Total
Summary Of Accounts Receivables And Contract Assets And Contract Liabilities Table [Text Block]
Summary Of Accounts Receivables And Contract Assets And Contract Liabilities Table [Text Block]
Summary of Accounts Receivable, Contract Assets and Deferred Revenue
Other Accrued Liabilities, Current
Other accrued expenses and current liabilities
Other
Service [Member]
Service [Member]
2015 Employee Stock Purchase Plan.
Two Thousand Fifteen Employee Stock Purchase Plan [Member]
2015 Employee Stock Purchase Plan [Member]
Cash and Cash Equivalent
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Nippon Shinyaku Collaboration and License Agreement [Member]
Nippon Shinyaku collaboration and license agreement.
Cost Of License And Royalty Revenues
Cost of license and royalty revenues.
Cost of license and royalty revenues
Impairment losses recorded to right-of-use assets
Operating Lease, Impairment Loss
Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset
Carrying value of the asset
Common Stock, Shares, Issued
Common stock, shares issued
Asset Class [Domain]
Asset Class
Statement [Table]
Statement [Table]
November seven two thousand twenty four.
November Seven Two Thousand Twenty Four [Member]
November 7, 2024
Increase (Decrease) in Prepaid Expense
Prepaid expenses
Two Thousand Fourteen And Two Thousand Fifteen Equity Incentive Plan [Member]
Two Thousand Fourteen And Two Thousand Fifteen Equity Incentive Plan [Member]
2014 and 2015 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average fair values of options granted
First Anniversary.
First Anniversary [Member]
First Anniversary [Member]
Statement [Line Items]
Statement [Line Items]
Loan Agreement with HCR [Member]
Loan Agreement with HCR.
Entity Filer Category
Entity Filer Category
Reclassifications
Reclassification, Comparability Adjustment [Policy Text Block]
Variable Consideration
Variable consideration.
Variable consideration
Liabilities and Equity
Total liabilities and stockholders’ equity
Payables and Accruals [Abstract]
Milestone fee payments upon commencement of clinical trials.
Milestone Fee Payments Upon Commencement Of Clinical Trials
Milestone payment upon commencement of clinical trials in humans
Payments to Acquire Marketable Securities
Purchases of marketable debt securities
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-average Exercise Price, Exercisable
Restructuring Type
Restructuring Type [Axis]
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset
Cash Equivalents and Marketable Securities [Member]
Cash Equivalents And Marketable Securities [Member]
Cash equivalents and marketable securities.
Personnel [Member]
Personnel.
Personnel
Furniture Fixtures and Leasehold Improvements [Member]
Furniture Fixtures and Leasehold Improvements [Member]
Restructuring and Related Costs [Table Text Block]
Summary of Restructuring Liability
Contract Termination Claims, Description
License agreement termination claims, description
Olivier Danos [Member]
Olivier Danos.
Olivier Danos [Member]
Cash and Cash Equivalents, Fair Value Disclosure
Total cash equivalents
Other Unbilled Receivables Non Current
Other unbilled receivables on current.
Other unbilled
Other
Other Assets, Miscellaneous, Current
Purchase price of share
Shares Issued, Price Per Share
Subsequent Event [Line Items]
Other Noncash Income (Expense)
Other non-cash adjustments
Other Noncash Income (Expense), Total
License and Service [Member]
License and royalty [Member]
Stock Options [Member]
Stock Options Outstanding [Member]
Investment Income, Interest
Interest income from investments
Two thousand twenty five Royalty Bond [Member]
Two thousand twenty five Royalty Bond [Member]
2025 Royalty Bond
Geographical [Domain]
Schedule Of Prepaid Expenses [Table Text Block]
Schedule of prepaid expenses.
Schedule of Prepaid Expenses
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Restricted Cash
GSK Settlement Agreement [Member]
GSK settlement agreement.
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Accounts Receivable, Allowance for Credit Loss
Allowance for credit losses
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Additional paid-in capital
Additional Paid in Capital, Common Stock
Accrued expenses and other current liabilities.
Accrued Expenses And Other Current Liabilities [Member]
Accrued Expenses and Other Current Liabilities [Member]
Related Party [Member]
License and Royalty Revenue [Member]
License and royalty revenue.
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Property, Plant and Equipment [Line Items]
Property Plant And Equipment [Line Items]
Prepaid Expense, Current [Abstract]
Share Repurchase Program [Axis]
Revenue recognized upon achievement of development milestones
Revenue Recognized Upon Achievement Of Development Milestones
Revenue recognized upon achievement of development milestones.
Milestone payment obligation.
Milestone Payment Obligation
Milestone payment obligation
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Shares, Granted
Itvisma royalties [Member]
Itvisma royalties.
Itvisma Royalties [Member]
Nippon Shinyaku Services [Member]
Nippon shinyaku services.
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of Computations of Basic and Diluted Net Income (Loss) Per Share
Royalty Monetization Liabilities [Abstract]
Royalty monetization liabilities.
Upfront and annual license fee receivable.
Upfront And Annual License Fee Receivable
Up-front and annual fees
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Basic net income (loss) per share
Basic
Vesting of restricted stock units
Vesting Of Restricted Stock Units
Vesting of restricted stock units, net of tax
OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax, Total
OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax
Income tax effects or reclassification adjustments
Service Agreements [Member]
Service Agreements [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Shares Outstanding, Ending Balance
Shares Outstanding, Beginning Balance
Accrued expenses and other current liabilities.
Accrued Expenses And Other Current Liabilities
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities
Liabilities, Current
Total current liabilities
Other Past or Future Obligations to Pay Sublicense Fees.
Other Past Or Future Obligations To Pay Sublicense Fees [Member]
Other Past or Future Obligations to Pay Sublicense Fees [Member]
Increase (Decrease) in Accounts Receivable
Accounts receivable
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Mitchell Chan [Member]
Mitchell Chan.
Royalty Agreements [Member]
Royalty Agreements
Share Repurchase Program [Domain]
Financing Receivable, Allowance for Credit Loss [Line Items]
Financing Receivable Allowance For Credit Losses [Line Items]
Accounts Receivable, after Allowance for Credit Loss, Noncurrent
Accounts receivable
Non-current accounts receivable
Accounts receivable, Non current
Other Current Assets [Line Items]
Other current assets.
Consolidation Items [Domain]
Equity, Attributable to Parent [Abstract]
Stockholders’ equity
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Other license and royalty revenue.
Other License And Royalty Revenue
Other license and royalty revenue
Other
Net proceeds allocated to Royalty Bond
Net proceeds allocated to royalty bond.
Net proceeds allocated to Royalty Bond
Proceeds from royalty bond, net of discount and issuance costs
Other Commitments [Line Items]
Other Commitments [Line Items]
Nature of Business
Nature of Operations [Text Block]
Change in transaction price of license.
Change In Transaction Price Of License
Change in transaction price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Shares, Cancelled or forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Total intrinsic value of options exercised
A N Jerry Karabelas [Member]
A N Jerry Karabelas.
A N Jerry Karabelas [Member]
Other Current Assets [Member]
Other Current Assets [Member]
Share-Based Payment Arrangement [Text Block]
Stock-based Compensation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Leases [Abstract]
Sales based milestones.
Sales Based Milestones [Member]
Sales Based Milestones
Weighted Average Number of Shares Outstanding, Diluted, Adjustment
Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total
Weighted-average common shares outstanding
Contract with Customer, Liability
Balance, end of period
Balance, beginning of period
Deferred revenue, current and non-current
Contract with Customer, Liability, Total
Amendment Flag
Amendment Flag
Product and Service [Domain]
Product and Service
Direct Development And Support [Member]
Direct development and support.
Direct development and support
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of warrants issued
Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share
Net Income (Loss) Per Share
Liabilities and Equity [Abstract]
Liabilities and Stockholders’ Equity
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Royalty payment cap amount
Royalty Payment Cap Amount
Royalty Payment Cap Amount
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash provided by (used in) operating activities
Contract assets.
Contract Assets [Member]
Contract Assets [Member]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Stock [Member]
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]
Schedule of Collaboration Agreement
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted-average Exercise Price, Granted
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance
Amortization of Debt Discount (Premium)
Debt discount
Debt Securities, Available-for-Sale [Line Items]
Schedule Of Available For Sale Securities [Line Items]
May two thousand twenty five warrants [Member]
May two thousand twenty five warrants.
May 2025 Warrants [Member]
Debt Instrument, Interest Rate, Effective Percentage
Interest Rate, Effective Percentage
Entity Address, Address Line One
Entity Address, Address Line One
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Earnings Per Share [Abstract]
Net income (loss) per share:
Name of Property [Axis]
Other Liabilities [Member]
Other Liabilities [Member]
Statement of Financial Position Location, Balance [Axis]
Balance Sheet Location
Investment Type [Axis]
Investment Type
Vittal Vasista [Member]
Vittal Vasista.
Vittal Vasista [Member]
Operating Lease, Right-of-Use Asset
Operating lease right-of-use assets
Debt Securities, Available-for-Sale, Unrealized Loss Position
Total, Fair Value
Aggregate transaction price of license agreements.
Aggregate Transaction Price Of License Agreements
Aggregate transaction price of license agreements
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
Unrealized gain (loss) on available-for-sale securities, net
Unrealized loss on available-for-sale securities, net
Available for sale debt securities remaining maturities greater than one years
Available for sale debt securities remaining maturities greater than one years
Present value of cost of revenue.
Present Value Of Cost Of Revenue
Present value of cost of revenue
Class of Warrant or Right [Axis]
Document Type
Document Type
HCR.
H C R [Member]
HCR [Member]
HCR
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Cost of Revenue [Abstract]
Cost of License and Royalty Revenues [Abstract]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
Debt Securities, Available-for-Sale [Table Text Block]
Summary of Company Marketable Securities
Other [Member]
Other.
Other [Member]
Investments, Debt and Equity Securities [Abstract]
Royalty Monetization Liabilities [Line Items]
Royalty monetization liabilities.
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net increase (decrease) in cash and cash equivalents and restricted cash
Proceeds from stock options exercised Including unsettled options.
Proceeds From Stock Options Exercised Including Unsettled Options
Proceeds from stock options exercised including unsettled options
Subsequent Event Type [Domain]
Impairment losses recorded to property and equipment
Impairment loss Of property and equipment, net.
Impairment Loss Of Property and Equipment Net
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding
Restructuring Reserve, Period Increase (Decrease), Total
Restructuring Reserve, Period Increase (Decrease)
Reductions in restructuring liability
Common Stock, Par or Stated Value Per Share
Common stock, par value
FOXKISER limited liability partnership.
F O X K I S E R Limited Liability Partnership [Member]
FOXKISER LLP [Member]
March two thousand twenty four public offering.
March Two Thousand Twenty Four Public Offering [Member]
March 2024 Public Offering [Member]
Operating Costs and Expenses, Total
Operating Costs and Expenses
Related Party Transcation, Expenses from Transcations with Related Party
Related party transaction expense
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average Remaining Contractual Life (Years) Outstanding
Increase (Decrease) in Other Operating Liabilities
Other liabilities
Increase (Decrease) in Other Operating Liabilities, Total
Amortized Cost / Cost
Debt Securities, Available-for-Sale, Amortized Cost
Debt Securities, Available-for-Sale
Fair Value
Debt Securities, Available-for-Sale, Total
AbbVie collaboration and license agreement.
Abb Vie Collaboration And License Agreement [Member]
Abb Vie Collaboration And License Agreement
2020 Royalty Purchase Agreement
Two thousand twenty Royalty Purchase Agreement [Member]
Two thousand twenty royalty purchase agreement.
Exercise of stock options, net of tax, shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Shares, Exercised
Other
Other Prepaid Expense, Current
Estimated fair value of warrants
Estimated fair value of warrants
Estimated fair value of warrants.
Liability related to interest expense recognized.
Liability Related To Interest Expense Recognized
Interest expense recognized
Accrued Liabilities, Current
Accrued Liabilities, Current, Total
Accrued expenses, current
Current Fiscal Year End Date
Current Fiscal Year End Date
Other Operating Expenses Income
other operating expenses income.
Other operating expenses
Other operating expenses
Prepaid External Research And Development Expenses
Prepaid external research and development expenses.
Prepaid external research and development expenses
Restricted Cash and Cash Equivalent, Noncurrent
Restricted cash
Restricted Cash and Cash Equivalents, Noncurrent, Total
Document Quarterly Report
Document Quarterly Report
Schedule of Royalty Monetization Liabilities [Table Text Block]
Schedule of royalty monetization liabilities.
Schedule of Royalty Monetization Liabilities
Entity Address, State or Province
Entity Address, State or Province
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Unvested balance at December 31, 2025
Unvested balance at March 31, 2026
Curran Simpson [Member]
Curran Simpson.
Curran Simpson [Member]
License revenue.
License Revenue [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
November two thousand twenty two license agreement.
November Two Thousand Twenty Two License Agreement [Member]
November Two Thousand Twenty Two License Agreement
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive income (loss)
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Unrealized Gains
Common Stock, Capital Shares Reserved for Future Issuance
Common stock reserved for issuance
Class of Warrant or Right [Domain]
Geographical [Axis]
Contract with Customer, Liability, Revenue Recognized
Revenue recognition, milestone method, revenue recognized
Revenue recognized
Equity incentive plans [Member]
Equity incentive plans.
Equity Incentive Plans [Member]
Marketable Securities, Current
Marketable securities
Laboratory and manufacturing equipment Member
Laboratory And Manufacturing Equipment [Member]
Laboratory and Manufacturing Equipment [Member]
Novartis royalties paid to HCR
Payments for Royalties
Novartis royalties paid to HCR
Accounts receivable, Non-current
Accounts Receivable, before Allowance for Credit Loss, Noncurrent
Accounts Receivable, before Allowance for Credit Loss, Noncurrent, Total
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Stock-Based Compensation Expense
Exercise of stock options, net of tax
Stock Issued During Period, Value, Stock Options Exercised
Proceeds from Royalties Received
Proceeds from Royalties Received
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Supplemental Disclosures
Collaborative Arrangement Disclosure [Text Block]
License and Collaboration Agreements
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive Loss
Unvested PSUs [Member]
Performance Shares [Member]
PSUs [Member]
Proceeds from Sale and Maturity of Marketable Securities
Maturities of marketable debt securities
Subsequent Event [Member]
Deferred Revenue, Current
Deferred Revenue, Current, Total
Deferred revenue, Current
Property, Plant and Equipment [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized
Additional shares to be issued
Billed Contracts Receivable
Billed to customers
Other Assets, Noncurrent
Other assets
Debt instrument final payment premium percentage
Debt instrument final payment premium percentage.
Final payment premium percentage
Antidilutive Securities
Antidilutive Securities [Axis]
Revenue, Product and Service [Extensible Enumeration]
Types of Revenue[Extensible List]
License fees.
License Fees [Member]
License Fees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Aggregate Intrinsic Value, Vested and expected to vest
Significant Accounting Policies.
Significant Accounting Policies [Line Items]
Significant Accounting Policies [Line Items]
Related Party Transaction [Axis]
Related Party Transaction
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Loss [Member]
Exercise of pre-funded warrants
Stock Issued During Period Shares Exercise Of Prefunded Warrants
Stock issued during period shares exercise of prefunded warrants.
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name
Cash and Cash Equivalents [Domain]
Cash and Cash Equivalents
Other Commitments [Table]
Other Commitments [Table]
Schedule Of License Revenue [Table Text Block]
Schedule Of License Revenue Table [Text Block]
Schedule Of Revenues Earned Under License and Collaboration Agreements
Preferred Stock, Value, Issued
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at March 31, 2026 and December 31, 2025
Revenue Recognition, Milestone Method, Revenue Recognized
Revenue recognized
Revenue recognition, milestone method, revenue recognized
March 2024 Public Offering and Pre-funded Warrants [Member]
March 2024 Public Offering and Pre-funded Warrants member.
March 2024 Public Offering and Pre-funded Warrants [Member]
University of Pennsylvania.
University Of Pennsylvania [Member]
University of Pennsylvania [Member]
Debt Instrument, Maturity Date
Debt instrument, maturity date
Minimum [Member]
Minimum [Member]
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average Grant Date Fair Value, Granted
Financial Instrument [Axis]
Financial Instrument
Assets, Current [Abstract]
Current assets
Fair Value, Inputs, Level 3 [Member]
Level 3
Segment Reporting [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of Fair Value of Cash Equivalents and Marketable Securities
Cost of License and Royalty Revenues [Member]
Total Cost Of License And Royalty Revenues [Member]
Total cost of license and royalty revenues.
Liabilities, Current [Abstract]
Current liabilities
Interest accrual percentage.
Interest Accrual Percentage
Interest percentage on unpaid balances under license agreement
Restructuring and Related Activities Disclosure [Text Block]
Restructuring
November two thousand eighteen license agreement.
November Two Thousand Eighteen License Agreement [Member]
November Two Thousand Eighteen License Agreement
Related Party Transactions [Abstract]
Shares, Outstanding
Balances (Shares)
Balances (Shares)
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater
Sublease Income
Sublease income
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts receivable, Current
Accounts receivable
Deferred transaction cost.
Deferred Transaction Cost
Deferred Transaction Cost
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-average Grant Date Fair Value, Unvested Beginning Balance
Weighted-average Grant Date Fair Value, Unvested Ending Balance
General and Administrative Expense [Member]
General and Administrative Expense [Member]
General and Administrative [Member]
Other [Member]
Other cost of license and royalty revenues [Member]
Other cost of license and royalty revenues.
Debt Instrument, Basis Spread on Variable Rate
Interest rate
Accounts Receivable, before Allowance for Credit Loss, Current
Accounts receivable, current
Forecast [Member]
Schedule of cash and cash equivalents and restricted cash.
Schedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block]
Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash
Provision for Other Credit Losses
Provision for credit losses
Milestone fee received upon achievement of specified development and sales based milestones
Milestone Fee Received Upon Achievement Of Specified Development And Sales Based Milestones
Milestone fee received upon achievement of specified development and sales based milestones.
Marketable Securities, Noncurrent
Marketable securities
Zolgensma Royalties Itvisma [Member]
Zolgensma Royalties Itvisma [Member]
Zolgensma Royalties Itvisma [Member]
Lessee, Lease, Description [Table]
Accounts receivable net non current.
Accounts Receivable Table Text Block1
Summary of Accounts Receivables
Capital Expenditures Incurred but Not yet Paid
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net income (loss)
Royalty Monetization Liabilities
Royalty monetization liabilities.
Royalty monetization liabilities
Ending balance
Beginning balance
Novartis gene therapies.
Novartis Gene Therapies [Member]
Novartis Gene Therapies [Member]
Long-Term Debt, Type [Domain]
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted-average common shares outstanding
Basic
Scenario [Axis]
New york sublease.
New York Sublease [Member]
Milestone fee payments upon submission preclinical filings.
Milestone Fee Payments Upon Submission Preclinical Filings
Milestone fee upon submission of preclinical regulatory filings
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate Intrinsic Value, Exercisable
Transaction costs associated with stock issuance.
Transaction Costs Associated With Stock Issuance
Issuance of Stock, transaction costs
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
12 Months or Greater, Unrealized Losses
Long-Lived Tangible Asset [Domain]
Long-Lived Tangible Asset
Subsequent Events
Subsequent Events [Text Block]
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Interest rate terms
Debt Instrument, Interest Rate Terms
Variable Rate [Domain]
Repurchase of call option amount
Repurchase of call option amount
Repurchase Of Call Option Amount
Equity, Attributable to Parent
Balances
Balances
Total stockholders’ equity
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Accounts Receivable, after Allowance for Credit Loss, Noncurrent [Abstract]
Non-current accounts receivable:
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation
November two thousand twenty one license agreement.
November Two Thousand Twenty One License Agreement [Member]
November Two Thousand Twenty One License Agreement
Statement of Stockholders' Equity [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Type of Restructuring [Domain]
Type of Restructuring
Cash Equivalents [Member]
Cash Equivalents [Member]
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Milestone fee payments upon achievement of various development and commercialization.
Milestone Fee Payments Upon Achievement Of Various Development And Commercialization
Milestone fee payments upon achievement of various development and commercialization
Leasehold Improvements [Member]
Leasehold Improvements [Member]
Financing Receivable, Allowance for Credit Loss
Ending Balance
Beginning Balance
Entity Address, Address Line Two
Entity Address, Address Line Two
Fair Value Disclosures [Text Block]
Fair Value Measurements
Warrants expiration period
Warrants expiration period.
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
Stock-Based Compensation Expense by Award Type
Zolgensma Royalties .
Zolgensma Royalties [Member]
Zolgensma Royalties [Member]
Accrued external research and development expenses.
Accrued External Research And Development Expenses
Accrued external research and development expenses
Unbilled
Unbilled receivables non current.
Unbilled Receivables Non Current
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Debt Instrument, Name [Domain]
Other Assets, Current
Other current assets
Other Assets, Current, Total
Noncash Investing and Financing Items [Abstract]
Supplemental disclosures of non-cash investing and financing information
November two thousand twenty four license agreement.
November Two Thousand Twenty Four License Agreement [Member]
November Two Thousand Twenty Four License Agreement
Additional percentage of amount payable upon repayment of debt
Additional percentage of amount payable upon repayment of debt
Additional percentage of amount payable upon repayment of debt.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Segment Reporting, Other Segment Item, Amount
Other segment items
Other segment items
Plan Name [Domain]
Plan Name
Interest Expense, Operating and Nonoperating
Interest expense
Interest expense
Interest Expense, Total
Upfront license fee paid.
Upfront License Fee Paid
Up-front fee paid
Receivable [Policy Text Block]
Accounts Receivable
Contract Termination [Member]
Contract Termination
Total impairment of long-lived assets
Impairment of long-lived assets
Impairment of loss
Property and equipment, net
Impairment of property and equipment
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Weighted-average Exercise Price, Vested and expected to vest
Certificates of Deposit [Member]
Certificates of Deposit [Member]
Pre-funded warrants remained outstanding
Class of Warrant or Right, Outstanding
Warrants/Prefunded Warrants remained outstanding
Summary of Impairment Losses Allocated to Various Assets Within Long-lived Asset Group Based on Relative Carrying Values
Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]
Novartis royalties [Member]
Novartis royalties.
Novartis Royalties [Member]
Related and Nonrelated Parties [Axis]
Related Party
Revenue recognized performance obligation.
Revenue Recognized Performance Obligation
Performance obligations satisfied in previous periods
Entity Address, City or Town
Entity Address, City or Town
Restructuring Reserve, Translation and Other Adjustment
Other adjustments
Royalty Monetization Liabilities [Table]
Royalty Monetization Liabilities.
Security Exchange Name
Security Exchange Name
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]
Property, Plant and Equipment, Gross
Total property and equipment
Property, Plant and Equipment, Gross, Total
Property, Plant and Equipment, Gross, Beginning Balance
Property, Plant and Equipment, Gross, Ending Balance
Milestone fee payments upon achievement of specified sales targets.
Milestone Fee Payments Upon Achievement Of Specified Sales Targets
Milestone payment upon achievement of specified sales targets for licensed products
November 8, 2024
November eight two thousand twenty four.
November Eight Two Thousand Twenty Four [Member]
Non cash interest expense.
Non Cash Interest Expense
Non-cash interest expense
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Related party transaction expenses (revenue) from transactions with related party.
Related Party Transaction Expenses Revenue From Transactions With Related Party
Related party transaction expense
Total related party transaction expense
Total related party transaction expense
Unpaid interest accrued to principal
Debt Instrument, Increase, Accrued Interest
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Total cash and cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance
Statistical Measurement [Domain]
Statistical Measurement
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants
Assets, Current
Total current assets
Stock-based compensation expense
Share-Based Payment Arrangement, Expense
Document Period End Date
Document Period End Date
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Shares, Exercisable
Accrued Interest on Investments
Accrued interest on investments.
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs)
Unvested RSUs [Member]
Revenue [Policy Text Block]
Revenue Recognition
Due from and to related parties current.
Due From And To Related Parties Current [Abstract]
Net cost reimbursement to (from) AbbVie included in:
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
License revenue.
License Revenue [Table]
License Revenue [Table]
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Cash and cash equivalents and restricted cash
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions
Number of investment grade fixed income debt security
Total cost of revenues.
Total Cost Of Revenues [Member]
Cost of Revenues [Member]
Purchase Agreement
Purchase agreement.
Purchase Agreement
Other Receivables
Due from related parties
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total
Debt Securities, Available-for-Sale, Realized Gain (Loss)
Realized gains or losses on available-for-sale securities
Liabilities
Total liabilities
Financial Instruments [Domain]
Financial Instruments
Increase (Decrease) in Deferred Revenue
Deferred revenue
Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale
Other-than-temporary impaired
400 Madison Lease [Member]
NEW YORK
Variable Rate [Axis]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Less than 12 Months, Unrealized Losses
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted-average diluted common shares
Diluted
Securities Act File Number
Entity File Number
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized gain on available-for-sale securities, net
Unrealized loss on available-for-sale securities, net
Cover [Abstract]
Second disbursal of loan amount
Second disbursal of loan amount.
Second disbursal of loan amount
Vesting of restricted stock units, net of tax, shares
Vesting of Restricted Stock Units Shares
Vesting Of Restricted Stock Units Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Forfeited
Shares, Forfeited
Investments
Investments [Domain]
Milestone Payment Upon First Patient Dosed in the Subsequent Phase III Trial
Milestone payment upon first patient dosed in the subsequent phase III trial.
Milestone payment upon first patient dosed in the subsequent Phase III trial
Scenario [Domain]
Milestone Payment Upon First Patient Dosed in Phase Second or Third Trial
Milestone payment upon first patient dosed in phase second or third trial.
Milestone payment upon first patient dosed in the Phase IIb/III trial
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Common stock shares authorized for issuance
Sale of Stock [Domain]
Royalty Bond [Member]
Royalty bond.
2025 Royalty Bond
Segment Reporting Disclosure [Text Block]
Segment Information
General and Administrative Expense
General and administrative
General and Administrative Expense, Total
Total general and administrative expense
Revenue from Contract with Customer, Including Assessed Tax
Total license and royalty revenue
Total revenues
Royalties on net sales of Zolgensma and Itvisma
Percentage of reduction in workforce.
Percentage Of Reduction In Workforce
Percentage of reduction in workforce
Subsequent Event [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period
Common stock shares issued to participants
Issuance of warrants, net of transaction costs
Adjustments to Additional Paid in Capital, Warrant Issued
Warrants issued
Sublicense fees previously recognized.
Sublicense Fees Previously Recognized
Sublicense fees previously recognized
Marketable Securities [Abstract]
Marketable securities:
Restructuring Charges
Restructuring Charges, Total
Restructuring charges
Restructuring costs
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Contract with Customer, Liability, Current
Deferred revenue
Penn Letter Agreement.
Penn Letter Agreement [Member]
Penn Letter Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period
Transaction price of license.
Transaction Price Of License
Transaction price of license
Service Revenue [Member]
Service revenue.
Other Receivables, Net, Current, Total
Due from Abeona, net of present value discount
Due from related parties, current
Due from related parties, current
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Operating Lease, Liability, Current
Operating lease liabilities
Document Transition Report
Document Transition Report
Number of equal annual installments.
Number Of Equal Annual Installments
Number of equal annual installments
Operating lease right- of-use assets.
Increase Decrease In Operating Lease Right Of Use Assets
Operating lease right-of-use assets
Stock plan expiration date.
Stock Plan Expiration Date
Stock plan expiration date
Debt issuance discount percentage
Debt issuance discount percentage.
Debt issuance discount percentage
Research and Development Expense
Research and development
Research and Development Expense, Total
Total research and development expense
Other Service Revenue [Member]
Other service revenue.
Other [Member]
Asset Impairment Charges
Property and equipment, net
Total impairment of long-lived assets
Impairment losses of long-lived assets
Impairment of long-lived assets
Lessee, Operating Leases [Text Block]
Leases
Stock-based compensation
Stock Based Compensation [Member]
Stock based compensation.
Revenue Recognition and Deferred Revenue [Abstract]
Revenue recognized during the period from:
Statement of Cash Flows [Abstract]
Novartis license agreement.
Novartis License Agreement [Member]
Novartis License Agreement [Member]
Stock Issued During Period, Value, New Issues
Issuance of common stock and pre-funded warrants
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Summary of Stock Option Activity
Expenses Related to At-the-market Offering Programs
Expenses related to at-the-market offering programs.
Expenses related to at-the-market offering program
Equity [Text Block]
Capitalization
Earnings Per Share [Text Block]
Net Income (Loss) Per Share
Computer Equipment [Member]
Computer Equipment and Software [Member]
Net income (loss)
Net income (loss)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate Intrinsic Value Outstanding
Warrants contractual term
Warrants and Rights Outstanding, Term
Settlement agreement.
Settlement Agreement [Member]
Settlement Agreement
Directors Or Section 16 Reporting Officers [Member]
Directors or Section 16 reporting officers.
Directors or Section 16 Reporting Officers [Member]
Litigation Settlement, Amount Awarded to Other Party
Payment of settlement amount
400 Madison lease.
Four Hundred Madison Lease [Member]
400 Madison Avenue [Member]
Provision for Loan, Lease, and Other Losses
Provision for credit losses
Provision for credit losses
Provision for Loan, Lease, and Other Losses, Total
Accounts Receivable, before Allowance for Credit Loss
Accounts receivable
Assets [Abstract]
Assets
Amortization of debt discount and issuance costs
Amortization of Debt Issuance Costs and Discounts
Amortization of Debt Issuance Costs and Discounts, Total
Name of Property [Domain]
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Summary of unrealized loss on available-for-sale securities, net, presented in the consolidated statements of operations and comprehensive loss
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Cash flows from investing activities
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Interest expense
Interest Expense, Nonoperating, Total
Interest Expense, Nonoperating
Research and Development Expense [Member]
Research and Development Expense [Member]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Marketable Securities
Share based compensation arrangement by share based payment award outstanding number
Share based compensation arrangement by share based payment award outstanding number.
Awards remained outstanding
Litigation Settlement, Loss
Litigation loss
Increase (Decrease) in Other Noncurrent Assets
Other assets
Deferred Revenue
Deferred Revenue, Total
Deferred revenue
May Two Thousand Twenty Five Warrants Outstanding [Member]
May two thousand twenty five warrants outstanding.
May 2025 Warrants Outstanding
Restructuring Cost and Reserve [Line Items]
Other costs of revenue.
Other Costs Of Revenue [Member]
Other Costs Of Revenue [Member]
Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Interest income from licencing.
Interest Income From Licencing
Interest income from licensing
Number of Countries in which licensed patents
Number of Countries in which licensed patents
Number of countries in which licensed patents
Contract assets
Contract with Customer, Asset, after Allowance for Credit Loss, Current
Balance, end of period
Balance, beginning of period
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total
Number of commercial product candidates.
Number Of Commercial Product Candidates
Number of commercial product candidates
Debt Instrument [Axis]
Settlement Payment [Member]
Settlement payment.
Share-Based Payment Arrangement [Abstract]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Unrecognized stock-based compensation expense
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Assets, Fair Value Disclosure
Total cash equivalents and marketable securities
Estimated fair value of asset
Sale of Stock [Axis]
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised
Proceeds from issuance of common stock under employee stock purchase plan
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
Summary of Unvested RSUs Activity Under Equity Incentive Plans
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by investing activities
Private Placement [Member]
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Investment Income, Net
Investment income
Investment Income, Net, Total
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted-average Exercise Price, Cancelled or forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-average Grant Date Fair Value, Forfeited
Money Market Funds [Member]
Money Market Mutual Funds [Member]
Related and Nonrelated Parties [Domain]
Related Party
Income Taxes
Income Tax Disclosure [Text Block]
Debt Securities, Available-for-Sale, Allowance for Credit Loss
Allowance for credit loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance
Facilities
Facilities [Member]
Facilities.
Other Liabilities, Noncurrent
Other liabilities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities
Property, Plant and Equipment [Table Text Block]
Schedule of Property and Equipment
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted-average Exercise Price, Outstanding, Ending Balance
Weighted-average Exercise Price Outstanding, Beginning Balance
Description of debt disbursal
Description of debt disbursal
Description of debt disbursal.
Income Tax Disclosure [Abstract]
Additional Paid-in Capital [Member]
Additional paid in capital [Member]
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued expenses and other current liabilities
March 2024 Pre-funded Warrants [Member]
March 2024 Pre-funded Warrants member.
March 2024 Pre-funded Warrants [Member]
Liability related to non cash interest expense.
Liability Related To Non Cash Interest Expense
Non Cash Interest Expense
Statement of Income Location, Balance [Axis]
Income Statement Location
Trading Symbol
Trading Symbol
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment, Net
Depreciation And Amortization [Member]
Depreciation and amortization.
Depreciation and amortization
Shares Used In Computation Basic [Abstract]
Shares used In computation basic.
Shares used in computation:
Related Party Transaction [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Subsequent Event Type [Axis]
Employee-related Liabilities, Current
Accrued personnel costs
Employee-related Liabilities, Current, Total
Financing Receivable, Allowance for Credit Loss [Table Text Block]
Summary of Changes in Allowance For Credit Losses
Third disbursal of loan amount
Third disbursal of loan amount
Third disbursal of loan amount.
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Cash flows from financing activities
Total undiscounted payments
Lessee, Operating Lease, Liability, to be Paid, Total
Lessee, Operating Lease, Liability, to be Paid
Accrued Royalties And Sublicense Fees
Accrued royalties and sublicense fees.
Accrued royalties and sublicense fees
Receivables and contract assets.
Receivables And Contract Assets [Abstract]
Contract assets:
Equity Components [Axis]
Common Stock [Member]
Accounts and Financing Receivable, after Allowance for Credit Loss
Total accounts receivable
Nonoperating Income (Expense)
Total other income (expense)
Equity Component [Domain]
Equity Component
Asset Class [Axis]
Asset Class
Deferred Revenue, Noncurrent
Deferred Revenue, Noncurrent, Total
Deferred revenue, Noncurrent
Schedule of Capitalization [Table]
Increase (Decrease) in Other Current Assets
Other current assets
IPO [Member]
Public Offering [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Issuance of common stock under employee stock purchase plan, shares
Aggregate transaction price of license agreements, expected satisfaction period.
Aggregate Transaction Price Of License Agreements Expected Satisfaction Period
Aggregate transaction price of license agreements, expected satisfaction period
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Stock options expiration date
Operating lease liabilities.
Increase Decrease In Operating Lease Liabilities
Operating lease liabilities
Depreciation, Depletion and Amortization, Nonproduction
Depreciation and amortization
Depreciation, Depletion and Amortization, Nonproduction, Total
Repayments Under Royalty Monetization Liabilities, Net of Interest
Repayments under royalty monetization liabilities, net of interest.
Repayments under royalty monetization liabilities, net of interest
Other Assets [Abstract]
Nippon Shinyaku Licenses [Member]
Nippon shinyaku licenses.
Maximum [Member]
Maximum [Member]
Maximum
Number of Countries Where Licensed Patents Remain Active
Number of countries where licensed patents remain active.
Number of countries where licensed patents remain active
Percentage of common stock owned.
Percentage of Common Stock Owned
Percentage of common stock owned
Statistical Measurement [Axis]
Statistical Measurement
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-average Exercise Price, Exercised
Contract with Customer, Liability, Noncurrent
Deferred revenue
Accounts receivable, current
Receivables, Net, Current
Current accounts receivable
Prepaid Expense, Current
Prepaid expenses
Prepaid Expenses
Common Stock, Value, Issued
Common stock; $0.0001 par value; 100,000 shares authorized at March 31, 2026 and December 31, 2025; 51,617 and 50,892 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Property and Equipment [Member]
Property, Plant and Equipment [Member]
Financing Receivable, Allowance for Credit Loss [Table]
Schedule Of Financing Receivable Allowance For Credit Losses [Table]
Royalty Monetization Liabilities [Text Block]
Royalty monetization liabilities.
Royalty Monetization Liabilities
Cash and Cash Equivalents [Abstract]
Cash equivalents:
SOFR [Member]
Secured Overnight Financing Rate (SOFR) [Member]
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-lived Assets
Settlement agreement payable .
Settlement Agreement Payable
Settlement agreement payable
Accrued Liabilities
Accrued Liabilities, Total
Accrued expeses
License Agreement Revenue Recognition [Abstract]
License Agreement Revenue Recognition [Abstract]
Long-Term Debt, Term
Maturity term
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Milestone Due
Milestone due.
Milestone due
Costs and Expenses
Total operating expenses
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class
Shares Used In Computation Diluted [Abstract]
Shares used in computation diluted.
Shares used in computation:
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Total, Unrealized Losses
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Employee Stock [Member]
Employee Stock Purchase Plan [Member]
Entity Registrant Name
Entity Registrant Name
Royalty Monetization Liabilities noncurrent
Royalty monetization liabilities noncurrent.
Non-current portion
Royalty monetization liabilities
Non-current portion
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Unrealized Losses
Proceeds from sale of future royalties.
Proceeds From Sale Of Future Royalties
Proceeds from sale of future royalties
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
License fees.
License Fees
License fee
Debt instrument maturity date addational extension term
Debt instrument maturity date addational extension term.
Maturity date addtional extension term
Taxes paid related to net settlement of stock-based awards.
Taxes Paid Related To Net Settlement Of Stock Based Awards
Taxes paid related to net settlement of stock-based awards
Subsequent Events [Abstract]
Two Thousand And Fifteen Equity Incentive Plan [Member]
Two Thousand And Fifteen Equity Incentive Plan [Member]
2015 Equity Incentive Plan [Member]
NAV technology platform.
N A V Technology Platform [Member]
N A V Technology Platform [Member]
Abeona Therapeutics Inc
Abeona Therapeutics Incorporation [Member]
Abeona Therapeutics Incorporation
Proceeds from Issuance of Common Stock
Net proceeds from issuance of common stock
Costs and Expenses [Abstract]
Operating Expenses
Less:
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Deferred Revenue, Revenue Recognized
Amounts included in deferred revenue at beginning of period
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Consolidation Items [Axis]
Total service revenue.
Total Service Revenue [Member]
Cash payments
Payments for Restructuring
Cash payments
3-Month Secured Overnight Financing Rate [Member]
Three month Secured Overnight Financing Rate [Member]
Three month Secured Overnight Financing Rate.
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Shares, Granted
Accounts receivable net, current and non current.
Accounts Receivable Net Current And Non Current [Abstract]
Accounts receivable, current and non-current:
Assets
Total assets
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Current accounts receivable:
Property, Plant and Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted-average Remaining Contractual Life (Years), Exercisable
Income Statement [Abstract]
Restructuring Cost [Table]
Deferred Equity Offering Costs in Accounts Payable and Accrued Expenses and Other Current Liabilities
Deferred equity offering costs in accounts payable and accrued expenses and other current liabilities.
Deferred equity offering costs in accounts payable and accrued expenses and other current liabilities
Liability related to sale of future royalties.
Liability Related To Sale Of Future Royalties Current
Liability related to sale of future royalties
Current portion of liability related to sale of future royalties
Number of shares sold
Stock Issued During Period, Shares, New Issues
Issuance of common stock and pre-funded warrants, shares
Royalty Monetization Liabilities Current
Royalty monetization liabilities current.
Current portion
Current portion
Royalty monetization liabilities
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Vested
Shares, Vested
Vested
Earnings Per Share, Diluted [Abstract]
Diluted net income (loss) per share:
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Diluted net income (loss) per share
Diluted
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Segment Information
Operating Segments [Member]
Increase (Decrease) in Accounts Payable, Trade
Accounts payable
First disbursal of loan amount
First disbursal of loan amount
First disbursal of loan amount.
City Area Code
City Area Code
Other Comprehensive Income (Loss), Net of Tax
Total other comprehensive loss
Debt instrument extended maturity date
Debt instrument extended maturity date.
Debt instrument extended maturity date
Number of tranches of debt disbursal
Number of tranches of debt disbursal.
Number of tranches of debt disbursal
Debt Instrument, Face Amount
Aggregate amount
Other unbilled
Other Unbilled Receivables Current
Other unbilled receivables current.
Floor rate
Debt instrument floor rate
Debt instrument floor rate.
Due from and to related parties current.
Due From And To Related Parties Current
Total net cost reimbursement to (from) AbbVie
Changes in present value discount of receivables.
Changes In Present Value Discount Of Receivables
Changes in present value discount of receivables
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
Total intrinsic values vested
Issuance of common stock under employee stock purchase plan
Stock Issued During Period, Value, Employee Stock Purchase Plan
Two Thousand Twenty Five And Two Thousand Fifteen Equity Incentive Plan [Member]
Two thousand twenty five and two thousand fifteen Equity Incentive Plan.
2025 and 2015 Equity Incentive Plan [Member]
Segment Reporting Information [Line Items]
Lease expiration date
Lease Expiration Date
Pre funded warrants.
Pre Funded Warrants [Member]
Pre Funded Warrants [Member]
Development milestone.
Development Milestone [Member]
Development Milestone
Amount payable to net present value discount.
Amount Payable To Net Present Value Discount
Amount payable to net present value discount
Award Date [Axis]
Award Date
Property, Plant and Equipment, Net
Property and equipment, net
Property and equipment, net
Available for sale debt securities remaining maturities greater than three years.
Available For Sale Debt Securities Remaining Maturities Greater Than Three Years
Available for sale debt securities remaining maturities greater than three years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Shares, Vested and expected to vest
Beginning of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
End of period
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Corporate Bond Securities [Member]
Corporate Bonds [Member]
Operating Income (Loss)
Income (loss) from operations
Award Date [Domain]
Award Date
Milestone fee payment for all targets inclusive.
Milestone Fee Payment For All Targets Inclusive
Aggregate milestone payment for all the targets
Retained Earnings [Member]
Accumulated Deficit [Member]
Accrued purchases of property and equipment.
Accrued Purchases Of Property And Equipment
Accrued purchases of property and equipment
Milestone fee payments upon submission of regulatory approval filings.
Milestone Fee Payments Upon Submission Of Regulatory Approval Filings
Milestone payment upon submission of regulatory approval filings
Cash and Cash Equivalents [Axis]
Cash and Cash Equivalents
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense, Total
Other General And Administrative [Member]
Other general and administrative.
Other general and administrative
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Less than 12 Months, Fair Value
Available for sale debt securities remaining maturities greater than two years
Available for sale debt securities remaining maturities greater than two years
Operating Lease, Liability, Noncurrent
Operating lease liabilities
Fair Value, Inputs, Level 1 [Member]
Level 1
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash used in financing activities
Glaxo Smith Kline LLC.
Glaxo Smith Kline L L C [Member]
GlaxoSmithKline LLC [Member]
GlaxoSmithKline LLC [Member]
Schedule of Other Current Assets
Schedule of Other Current Assets [Table Text Block]
Nonoperating Income (Expense) [Abstract]
Other Income (Expense)
US Government Corporations and Agencies Securities [Member]
U.S. Government and Agency Securities [Member]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedules for Computation of Diluted Weighted-Average Shares Outstanding
Litigation liabilities
Estimated Litigation Liability
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Statement of Income Location, Balance [Domain]
Income Statement Location
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Cash flows from operating activities
Furniture and Fixtures [Member]
Furniture and Fixtures [Member]
Aggregate offering price
Aggregate Offering Price
Aggregate offering price.
Proceeds from Related Party Debt
Proceeds received, net of discounts and transaction costs
Operating lease commencement year.
Operating Lease Commencement Year
Operating Lease Commencement Year
Accretion (Amortization) of Discounts and Premiums, Investments
Net accretion of discounts on marketable debt securities
Sublicense Fees Due Or Owed in Future.
Sublicense Fees Due Or Owed In Future [Member]
Sublicense Fees Due Or Owed in Future [Member]
Unbilled Zolgensma royalties
Unbilled Receivables, Current
Unbilled
Schedule of changes in royalty monetization liability [Table Text Block]
Schedule of changes in royalty monetization liability.
Schedule of Changes in Royalty Monetization Liability
Milestone fee payments upon approval of commercial products.
Milestone Fee Payments Upon Approval Of Commercial Products
Milestone payment upon approval of commercial products by regulatory agencies
Class of warrant or right exercised.
Class Of Warrant Or Right Exercised
Warrants exercised
Two thousand and twenty five Fifteen Equity Incentive Plan [Member]
Two thousand and twenty five Fifteen Equity Incentive Plan.
2025 Equity Incentive Plan [Member]
Entity Tax Identification Number
Entity Tax Identification Number
Revenues [Abstract]
Revenues
Long-Term Debt, Type [Axis]
Debt instrument original issue discount and reimbursement of issuance costs
Debt instrument original issue discount and reimbursement of issuance costs.
Original issue discount and reimbursement of issuance costs
Local Phone Number
Local Phone Number
Related Party Transaction [Domain]
Related Party Transaction
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average common shares outstanding:
License and royalty revenue.
License And Royalty Revenue
Total license and royalty revenue
Accounting Policies [Abstract]
Employee stock purchase plan.
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Member]
Revenue from Contract with Customer, Excluding Assessed Tax
Revenues
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Shares available for future grants
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Unrecognized stock-based compensation, weighted-average period
Cash, Cash Equivalents, and Short-Term Investments
Cash, cash equivalents and marketable securities
Cash, Cash Equivalents, and Short-Term Investments, Total
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Schedules of Accrued Expenses and Other Current Liabilities
Other Current Assets [Table]
Other current assets
Entity Emerging Growth Company
Entity Emerging Growth Company
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average Remaining Contractual Life (Years), Vested and expected to vest
Significant Accounting Policies [Table]
Significant Accounting Policies.
Significant Accounting Policies [Table]